[A case of long survival with UFT and lentinan treatment in a patient with peritoneal metastasis of gastric carcinoma]

Gan To Kagaku Ryoho. 2004 Feb;31(2):241-3.
[Article in Japanese]

Abstract

The patient was a 50-year-old female with peritoneal metastasis of Type 4 gastric cancer. She underwent a relative curative resection with total gastrectomy and peritonectomy. Postoperative chemotherapy with 5'-DFUR following 5-FU and CDDP was performed. Thirteen months after surgery, cancer recurrence was suspected due to elevated levels of the serum tumor markers carcinoembryonic antigen (8.9 ng/ml) and alpha fetoprotein (85.8 ng/ml). She was additionally treated with UFT 300 mg/day and Lentinan 2 mg/week. The serum tumor markers decreased gradually returned to normal levels. At 5 years and 8 months after surgery, she is alive without any sign of recurrence.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / blood
  • Carcinoembryonic Antigen / blood
  • Carcinoma, Signet Ring Cell / drug therapy*
  • Carcinoma, Signet Ring Cell / secondary
  • Carcinoma, Signet Ring Cell / surgery
  • Chemotherapy, Adjuvant
  • Drug Administration Schedule
  • Drug Combinations
  • Female
  • Gastrectomy
  • Humans
  • Lentinan / administration & dosage
  • Middle Aged
  • Neoplasm Invasiveness
  • Peritoneal Neoplasms / drug therapy*
  • Peritoneal Neoplasms / secondary
  • Peritoneal Neoplasms / surgery
  • Peritoneum / surgery
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery
  • Survivors
  • Tegafur / administration & dosage
  • Uracil / administration & dosage
  • alpha-Fetoproteins / analysis

Substances

  • Biomarkers, Tumor
  • Carcinoembryonic Antigen
  • Drug Combinations
  • UFT(R) drug
  • alpha-Fetoproteins
  • Tegafur
  • Lentinan
  • Uracil